Recent findings from the DESTINY-PanTumor01 study have highlighted the expanding potential of ErbB2-targeted therapies beyond breast cancer, demonstrating that trastuzumab deruxtecan shows significant efficacy across multiple solid tumors with activating ErbB2 mutations. Here, ERBB2 is linked to breast carcinoma.